trial

An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia.

NCTId NCT06486948
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 58 (actual)
Sponsored by Click Therapeutics, Inc.
Primary completion 2024-08-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
58 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2024-05-06
Primary completion
2024-08-09
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
CT-156

Sponsors

Click Therapeutics, Inc.Lead Sponsor
Boehringer IngelheimCollaborator

Investigators

1
Shaheen LakhanStudy Director

Sites

1 total
New York, United States

Facts & assertions

4 sourced
Enrollment
58
Phase
NA
Primary Completion Date
2024-08-09
Status
COMPLETED
relationships
The graph out of here
drug
CT-156
drug
lead_sponsor
Click Therapeutics, Inc.
company
collaborator
Boehringer Ingelheim
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Shaheen Lakhan
person